Schmitt G, Pape H, Zamboglou N
Department of Radiation Oncology, University of Düsseldorf, FRG.
Strahlenther Onkol. 1990 Jan;166(1):61-2.
The five-year follow-up results of 221 patients treated with neutrons or a neutron-boost at the West German Tumour Centre, Essen, are presented. 94 patients with gross tumour were treated with neutrons alone. 127 patients without gross tumour left behind post surgery were irradiated using a "mixed beam" schedule. The disease-free survival rate at five years is 62.6% for T1-, 71.5% for T2- and 28.7% for T3-tumours (p = 0.016). Significant differences were also found for various grades, i.e. 73.3% for G1-, 47.7% for G2- (p = 0.035) and 22.4% for G3-tumours (p = 0.024). Patients without microscopic tumour residue fared best with a survival rate of 86.6%, followed by patients with microscopic tumour (65.5%; p = 0.042) and patients with gross tumour (25.5%; p = 0.003) left behind. A functional limb was preserved in 86% of the patients with extremity lesions. The local control rate of patients with gross tumour was 76.5% compared with 53% in previous photon series. This finding underlines the potential biological advantage of neutrons in these tumours. Serious side effects ranged from 28% in the patients treated with neutrons for large volumes to 7% in patients treated with a neutron boost.
本文展示了在德国埃森市西德肿瘤中心接受中子治疗或中子增强治疗的221例患者的五年随访结果。94例有肉眼可见肿瘤的患者仅接受了中子治疗。127例术后无肉眼可见肿瘤残留的患者采用“混合束”方案进行照射。T1期肿瘤的五年无病生存率为62.6%，T2期为71.5%，T3期为28.7%（p = 0.016）。在不同分级中也发现了显著差异，即G1级为73.3%，G2级为47.7%（p = 0.035），G3级为22.4%（p = 0.024）。无微小肿瘤残留的患者预后最佳，生存率为86.6%，其次是有微小肿瘤的患者（65.5%；p = 0.042）和有肉眼可见肿瘤残留的患者（25.5%；p = 0.003）。86%的肢体病变患者保留了功能肢体。有肉眼可见肿瘤的患者局部控制率为76.5%，而之前光子治疗系列的这一比例为53%。这一发现突出了中子在这些肿瘤中的潜在生物学优势。严重副作用的发生率在接受大体积中子治疗的患者中为28%，在接受中子增强治疗的患者中为7%。
